Our product candidate, THB001, is a first-in-class, highly selective, oral small-molecule KIT inhibitor in early clinical development for the treatment of severe allergic and mast cell-driven inflammatory diseases. Extensive preclinical studies demonstrate THB001 to have promising drug-like properties, excellent kinome selectivity, and potent mast cell depletion activity in all relevant tissue types. In early clinical studies, THB001 demonstrated robust pharmacodynamic effects as measured by serum tryptase, an established marker of mast cell activity and survival.
THB001 is initially in development for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts or hives.
Up to one percent of the U.S. population is believed to be affected by urticaria at some point in their lives. It is estimated that up to 90% of urticaria patients who have failed antihistamine therapy either fail or forego biologic therapy, leaving tremendous unmet need in a disease with known severe impacts on mental well-being and quality of life.